199 related articles for article (PubMed ID: 32200759)
1. Derivation and Application of a Tool to Estimate Benefits From Multiple Therapies That Reduce Recurrent Stroke Risk.
Richards A; Jackson NJ; Cheng EM; Bryg RJ; Brown A; Towfighi A; Sanossian N; Barry F; Li N; Vickrey BG
Stroke; 2020 May; 51(5):1563-1569. PubMed ID: 32200759
[TBL] [Abstract][Full Text] [Related]
2. Implementation of a structured guideline-based program for the secondary prevention of ischemic stroke in China.
Peng B; Ni J; Anderson CS; Zhu Y; Wang Y; Pu C; Wu J; Wang J; Zhou L; Yao M; He J; Shan G; Gao S; Xu W; Cui L;
Stroke; 2014 Feb; 45(2):515-9. PubMed ID: 24385269
[TBL] [Abstract][Full Text] [Related]
3. A benefit-risk assessment of agents used in the secondary prevention of stroke.
MacWalter RS; Shirley CP
Drug Saf; 2002; 25(13):943-63. PubMed ID: 12381215
[TBL] [Abstract][Full Text] [Related]
4. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
De Schryver EL; Algra A; van Gijn J
Cochrane Database Syst Rev; 2003; (1):CD001820. PubMed ID: 12535415
[TBL] [Abstract][Full Text] [Related]
5. [Secondary prevention after ischemic stroke].
Baumgartner RW; Georgiadis D
Praxis (Bern 1994); 2003 Jan; 92(5):168-78. PubMed ID: 12643070
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of a Chronic Care-Based Intervention on Secondary Stroke Prevention Among Vulnerable Stroke Survivors: A Randomized Controlled Trial.
Cheng EM; Cunningham WE; Towfighi A; Sanossian N; Bryg RJ; Anderson TL; Barry F; Douglas SM; Hudson L; Ayala-Rivera M; Guterman JJ; Gross-Schulman S; Beanes S; Jones AS; Liu H; Vickrey BG
Circ Cardiovasc Qual Outcomes; 2018 Jan; 11(1):e003228. PubMed ID: 29321134
[TBL] [Abstract][Full Text] [Related]
7. Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
Bohula EA; Wiviott SD; Giugliano RP; Blazing MA; Park JG; Murphy SA; White JA; Mach F; Van de Werf F; Dalby AJ; White HD; Tershakovec AM; Cannon CP; Braunwald E
Circulation; 2017 Dec; 136(25):2440-2450. PubMed ID: 28972004
[TBL] [Abstract][Full Text] [Related]
8. Quality of anticoagulation control in preventing adverse events in patients with heart failure in sinus rhythm: Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial substudy.
Homma S; Thompson JL; Qian M; Ye S; Di Tullio MR; Lip GY; Mann DL; Sacco RL; Levin B; Pullicino PM; Freudenberger RS; Teerlink JR; Graham S; Mohr JP; Labovitz AJ; Buchsbaum R; Estol CJ; Lok DJ; Ponikowski P; Anker SD;
Circ Heart Fail; 2015 May; 8(3):504-9. PubMed ID: 25850425
[TBL] [Abstract][Full Text] [Related]
9. Early aggressive medical management for patients with symptomatic intracranial stenosis.
Nahab F; Kingston C; Frankel MR; Dion JE; Cawley CM; Mitchell B; Hammonds LP; Ayala L; Tong FC
J Stroke Cerebrovasc Dis; 2013 Jan; 22(1):87-91. PubMed ID: 21795066
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole.
Chambers M; Hutton J; Gladman J
Pharmacoeconomics; 1999 Nov; 16(5 Pt 2):577-93. PubMed ID: 10662482
[TBL] [Abstract][Full Text] [Related]
11. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.
Hennekens CH; Schneider WR
Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):95-107. PubMed ID: 18095910
[TBL] [Abstract][Full Text] [Related]
12. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.
Hennekens CH; Sacks FM; Tonkin A; Jukema JW; Byington RP; Pitt B; Berry DA; Berry SM; Ford NF; Walker AJ; Natarajan K; Sheng-Lin C; Fiedorek FT; Belder R
Arch Intern Med; 2004 Jan; 164(1):40-4. PubMed ID: 14718320
[TBL] [Abstract][Full Text] [Related]
13. Secondary prevention of atherothrombotic cerebrovascular events.
Paciaroni M
Curr Vasc Pharmacol; 2014 May; 12(3):365-72. PubMed ID: 24846225
[TBL] [Abstract][Full Text] [Related]
14. Secondary stroke prevention: review of clinical trials.
Elkind MS
Clin Cardiol; 2004 May; 27(5 Suppl 2):II25-35. PubMed ID: 15188933
[TBL] [Abstract][Full Text] [Related]
15. Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration.
Simes J; Becattini C; Agnelli G; Eikelboom JW; Kirby AC; Mister R; Prandoni P; Brighton TA;
Circulation; 2014 Sep; 130(13):1062-71. PubMed ID: 25156992
[TBL] [Abstract][Full Text] [Related]
16. The role of warfarin and aspirin in secondary prevention of stroke.
Elkind MS
Curr Cardiol Rep; 2004 Mar; 6(2):135-42. PubMed ID: 14759359
[TBL] [Abstract][Full Text] [Related]
17. New perspectives on the pharmacotherapy of ischemic stroke.
Bradberry JC; Fagan SC; Gray DR; Moon YS
J Am Pharm Assoc (2003); 2004; 44(2 Suppl 1):S46-56; quiz S56-7. PubMed ID: 15095935
[TBL] [Abstract][Full Text] [Related]
18. Antiplatelet Therapy vs Anticoagulation Therapy in Cervical Artery Dissection: The Cervical Artery Dissection in Stroke Study (CADISS) Randomized Clinical Trial Final Results.
Markus HS; Levi C; King A; Madigan J; Norris J;
JAMA Neurol; 2019 Jun; 76(6):657-664. PubMed ID: 30801621
[TBL] [Abstract][Full Text] [Related]
19. How good is the management of vascular risk after stroke, transient ischaemic attack or carotid endarterectomy?
Johnson P; Rosewell M; James MA
Cerebrovasc Dis; 2007; 23(2-3):156-61. PubMed ID: 17124397
[TBL] [Abstract][Full Text] [Related]
20. Warfarin versus aspirin in the secondary prevention of stroke: the WARSS study.
Redman AR; Allen LC
Curr Atheroscler Rep; 2002 Jul; 4(4):319-25. PubMed ID: 12052284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
